Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model. | Synapse
February 27, 2026
Targeted nano delivery of p53 DNA and carvedilol for the treatment of dilated cardiomyopathy in a rat model.
Key Points
To evaluate the effectiveness of targeted nano delivery of p53 DNA and carvedilol for treating dilated cardiomyopathy.
Utilized targeted lipid-based nanoparticles for drug and gene delivery
Applied treatments in a rat model of dilated cardiomyopathy
Assessed biocompatibility and delivery efficiency of LANPs
Demonstrated improved myocardial delivery of p53 DNA and carvedilol
Resulted in significant therapeutic effects on cardiac function in the treated rats
Showed potential advantages over conventional delivery methods
Abstract
LANPs offer a promising, biocompatible platform for targeted myocardial delivery of gene and drug therapies and may serve as an effective strategy for treating cardiomyopathy.